Kenvue Inc.
KVUE
Rankning i aktier
#664
Kenvue Inc. functions as a global leader in the consumer health sector. The... Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
Aktiekurs
$19.18
Marknadsvärde
$36.83B
Förändring (1 dag)
-0.60%
Förändring (1 år)
28.43%
Land
US
Handel Kenvue Inc. (KVUE)
Kategori
Consumer Defensive
Vinst för Kenvue Inc. (KVUE)
Vinst i Jun 2026 TTM: $2.22B
Enligt de senaste finansiella rapporterna från Kenvue Inc. är företagets nuvarande vinst $2.22B. År 2023 hade företaget en vinst på $2.19B, en minskning jämfört med vinsten år 2022 som var $2.64B. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Kenvue Inc. från 2019 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2026 (TTM) | $2.22B | 57.10% |
| 2024 | $1.42B | -35.39% |
| 2023 | $2.19B | -16.95% |
| 2022 | $2.64B | -9.85% |
| 2021 | $2.93B | -387.89% |
| 2020 | $-1.02B | -147.92% |
| 2019 | $2.12B | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| $20.38B | 816.64% |
US
|
|
| $9.83B | 342.03% |
FR
|
|
| $2.94B | 32.30% |
US
|
|
| $1.55B | -30.27% |
IN
|
|
| $517.00M | -76.74% |
US
|
